Tetyana Falalyeyeva

Tetyana Falalyeyeva

Auto-generated profile, based on publicly available information

Tetyana Falalyeyeva

Taras Shevchenko National University of Kyiv, Kyiv, Ukraine

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
NKNazarii Kobyliak
Nazarii Kobyliak
TFTetyana Falalyeyeva
Tetyana Falalyeyeva
GMGalyna Mykhalchyshyn
Galyna Mykhalchyshyn
DKDmytro Kyriienko
Dmytro Kyriienko
IKIuliia Komissarenko
Iuliia Komissarenko

1 December 2015 in Nutrition Journal
Verified
Journal Article
Open access
PDF file
NKNazarii Kobyliak
Nazarii Kobyliak
OVOleksandr Virchenko
Oleksandr Virchenko
TFTetyana Falalyeyeva
Tetyana Falalyeyeva
Overweight and obesity increase the risk for a number of diseases, namely, cardiovascular diseases, type 2 diabetes, dyslipidemia, premature death, non-alcoholic fatty liver disease as well as different types of cancer. Approximately 1.7 billion people in the world suffer from being overweight, most notably in developed countries. Current research efforts have focused on host and environmental factors that may affect energy balance. It was hypothesized that a microbiota profile specific to an obese host with increased energy-yielding behavior may exist. Consequently, the gut microbiota is becoming of significant research interest in relation to obesity in an attempt to better understand the aetiology of obesity and to develop new methods of its prevention and treatment. Alteration of microbiota composition may stimulate development of obesity and other metabolic diseases via several mechanisms: increasing gut permeability with subsequent metabolic inflammation; increasing energy harvest from the diet; impairing short-chain fatty acids synthesis; and altering bile acids metabolism and FXR/TGR5 signaling. Prebiotics and probiotics have physiologic functions that contribute to the health of gut microbiota, maintenance of a healthy body weight and control of factors associated with obesity through their effects on mechanisms that control food intake, body weight, gut microbiota and inflammatory processes.

1 December 2017 in Journal of Digestive Diseases
Verified
Journal Article
Closed access
PDF file
ECElina G. Christian
Elina G. Christian
OVOleksandr Virchenko
Oleksandr Virchenko
TFTetyana Falalyeyeva
Tetyana Falalyeyeva
TBTetyana Beregova
Tetyana Beregova
Wolfgang StremmelWolfgang Stremmel
Wolfgang Stremmel

1 December 2018 in Minerva Medica
Verified
Journal Article
Closed access
NKNazarii Kobyliak
Nazarii Kobyliak
LALudovico Abenavoli
Ludovico Abenavoli
TFTetyana Falalyeyeva
Tetyana Falalyeyeva
GMGalyna Mykhalchyshyn
Galyna Mykhalchyshyn
LBLuigi Boccuto
Luigi Boccuto
ODOleg Dynnyk
Oleg Dynnyk
The manipulation of gut microbiota via administration of probiotics has been proposed as a potential strategy for the treatment of non-alcoholic fatty liver disease (NAFLD). Hence, we performed a double-blind single center randomized placebo-controlled trial (RCT) to evaluate the efficacy of coadministration of probiotics with omega-3 vs. placebo in type-2 diabetic patients with NAFLD. A total of 48 patients met the criteria for inclusion. They were randomly assigned to receive "Symbiter Omega" combination of probiotic biomass supplemented with flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%) or placebo for 8-weeks. The primary main outcomes were the change in fatty liver index (FLI) and liver stiffness (LS) measured by Shear Wave Elastography (SWE). Secondary outcomes were the changes in transaminases level, serum lipids and cytokines levels. In probiotic-omega group, FLI significantly decreased from 83.53±2.60 to 76.26±2.96 (P<0.001) while no significant changes were observed in the placebo group (82.86±2.45 to 81.09±2.84; P=0.156). Changes of LS in both groups were insignificant. Analysis of secondary outcomes showed that the coadministration of probiotics with omega-3 lead to significant reduction of serum gamma-glutamyl transpeptidase, triglycerides, and total cholesterol. Chronic systemic inflammatory markers after intervention decrease significantly only in Symbiter Omega group: IL-1β (P=0.029), TNF-α (P<0.001), IL-8 (P=0.029), IL-6 (P=0.003), and INF-γ (P=0.016). Coadministration of a live multi-strain probiotic mixture with omega-3 fatty acids once daily for 8 weeks to patients with NAFLD can reduce liver fat, improve serum lipids, metabolic profile, and reduce chronic systemic inflammatory state.

11 October 2018 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Ludovico AbenavoliLudovico Abenavoli
Ludovico Abenavoli
TFTetyana Falalyeyeva
Tetyana Falalyeyeva
Luigi BoccutoLuigi Boccuto
Luigi Boccuto
OTOlena Tsyryuk
Olena Tsyryuk
NKNazarii Kobyliak
Nazarii Kobyliak
The main treatments for patients with nonalcoholic fatty liver disease (NAFLD) are currently based on lifestyle changes, including ponderal decrease and dietary management. However, a subgroup of patients with nonalcoholic steatohepatitis (NASH), who are unable to modify their lifestyle successfully, may benefit from pharmaceutical support. Several drugs targeting pathogenic mechanisms of NAFLD have been evaluated in clinical trials for the treatment of NASH. Farnesoid X receptor (FXR) is a nuclear key regulator controlling several processes of the hepatic metabolism. NAFLD has been proven to be associated with abnormal FXR activity. Obeticholic acid (OCA) is a first-in-class selective FXR agonist with anticholestatic and hepato-protective properties. Currently, OCA is registered for the treatment of primary biliary cholangitis. However, promising effects of OCA on NASH and its metabolic features have been reported in several studies.

10 June 2015 in EPMA Journal
Verified
Journal Article
Open access
PDF file
NKNazarii Kobyliak
Nazarii Kobyliak
TFTetyana M. Falalyeyeva
Tetyana M. Falalyeyeva
OKOlena G. Kuryk
Olena G. Kuryk
TBTetyana V. Beregova
Tetyana V. Beregova
PBPetro M. Bodnar
Petro M. Bodnar
MSMykola Ya Spivak
Mykola Ya Spivak
Background: Male infertility has largely idiopathic, multifactorial origin. Oxidative stress is a major factor that affects spermatogenesis, in particular in aging. Cerium dioxide nanoparticles (CNPs) due to their antioxidative properties are promising to impact on the development of male infertility.The aimsof this study were to investigate the effects of CNPs on fertility parameters in 24-month male rats and to overview relevant literature in the field of personalized treatments, predictive diagnosis, and preventive measures for male health and fertility.Methods: We included 30 24-month-old male rats. After a week of adaptation to the standard diet, the rats were randomly divided into three groups with ten rats in each. Group 1 (controls) received only a standard diet. The rats of group 2 and 3 in adjunct to the standard diet during 10 days received intragastrically 10 % sodium citrate and citrate-coated CNPs in dose 1 mg/kg, respectively. We assessed sex hormones, epididymal sperm parameters and spermatogenesis, ultrasound, and morphological data of rat reproductive organs.Results: After a 10-day administration of CNPs, we revealed significant decrease of lipid peroxidation product levels in serum and increase of catalase and SOD activity, associated with increase of sperm count (p< 0.001) and improvement in quantitative sperm parameters (motility, viability, and percentage of spermatozoa). We found no significant changes between sperm quantitative parameters in citrate-treated rats and controls and observed age-related decrease of activated Leydig cell number and focal atrophy of the seminiferous tubules. In CNP group, we observed regeneration of seminiferous tubules, increase number and activation of Leydig cells, and 2.5-fold significant increase of serum testosterone. Ultrasound data showed the slight increase of linear measurement and volume of rat testes in CNP group. Review highlights the benefits for predictive diagnosis, preventive measures, and personalized approaches to manage male infertility in the general concept of male health also related to aging.Conclusion: Citrate-coated 2–5-nm CNPs lead to increase in sex hormones levels, sperm count, and quality, as well as the activation of spermatogenesis in 24-month-old male rats. Nanoceria demonstrated the perspectives to be an effective infertility treatment via reduction of oxidative stress in male reproductive organs, in particular in aging.